biostudies-literatureStavraka CCSP VACancer Research UKBritish Skin FoundationWorldwide Cancer ResearchBreast Cancer NowCancer Research UK King's Health Partners Centre at King's College LondonMedical Research CouncilCRUK/NIHR in England/DoH for Scotland, Wales and Northern Ireland Experimental Cancer Medicine CentreThe Cancer Research UK City of London Centre2225-2239https://www.ebi.ac.uk/biostudies/studies/S-EPMC12368751biostudies-literatureUnknown80(8)<h4>Background</h4>IgE antibodies directed against cancer antigens have demonstrated potent anti-tumour effects in pre-clinical studies. MOv18 IgE, the first-in-class IgE recognising the cancer antigen folate receptor alpha (FRα), showed preliminary signs of efficacy in a Phase I trial. Treatment was well tolerated, with the most common adverse event being transient urticarial skin reactions. We investigated immunological and allergic response parameters associated with urticarial skin reactions in MOv18 IgE-treated patients.<h4>Methods</h4>Expression of target antigen, FRα, and MOv18 IgE reactivity with FRα or any component in human skin was studied by immunohistochemistry, immunofluorescence and immuno-mass spectrometry. We conducted transcriptomic analyses in paired lesional and non-lesAllergyNon-Allergic Urticarial Skin Reactions Associated With MOv18 IgE, a First-In-Class IgE Antibody Recognising Folate Receptor Alpha.PMC12368751573147;KCL-BCN-Q3006/R/22C30122/A11527;C30122/A15774C604/A25135C7893/A29290MR/L023091/1;MR/V049445/1;MR/R015643/124-0087C10355/A15587Tull TJLacy KEMcGrath JChauhan JStavraka CGillett CKristeleit RMcSweeney SMDi Meo ATill SJPinder SPrassas IPope AStoker KWillsmore ZBax HJSpicer JCrescioli SKaragiannis SNGrattan CEHTsoka SMcCraw AJDiamandis EPJosephs DHNaban NAdams RCorrigan CJSemkova KVLaddach RfalseNon-Allergic Urticarial Skin Reactions Associated With MOv18 IgE, a First-In-Class IgE Antibody Recognising Folate Receptor Alpha.<h4>Background</h4>IgE antibodies directed against cancer antigens have demonstrated potent anti-tumour effects in pre-clinical studies. MOv18 IgE, the first-in-class IgE recognising the cancer antigen folate receptor alpha (FRα), showed preliminary signs of efficacy in a Phase I trial. Treatment was well tolerated, with the most common adverse event being transient urticarial skin reactions. We investigated immunological and allergic response parameters associated with urticarial skin reactions in MOv18 IgE-treated patients.<h4>Methods</h4>Expression of target antigen, FRα, and MOv18 IgE reactivity with FRα or any component in human skin was studied by immunohistochemistry, immunofluorescence and immuno-mass spectrometry. We conducted transcriptomic analyses in paired lesional and non-les2025-01-01T00:00:00Z2025 Aug2026-07-15T06:22:42.211Z2026-07-01T03:07:22.999ZS-EPMC123687514004592510.1111/all.16514